Project Grant HT94252510147

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports the development of a novel peptide-based therapeutic agent called M10 for the treatment of skin fibrosis associated with systemic sclerosis (scleroderma). The $613,036 award to Fibrobiologics LLC aims to determine the antifibrotic activity of M10 in primary skin fibroblasts from scleroderma...

This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $149,008 Cooperative Agreement under the Trans-NIH Research Support program (CFDA 93.310) to Cartesian Therapeutics Inc. to develop and evaluate a novel cell therapy for the treatment of systemic lupus erythematosus (SLE). The funding will support a Phase 2A clinical trial and the design of a subsequent randomized, placebo-controlled Phase 2B trial to test "Descartes-08", an RNA-engineered chimeric antigen...

This Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) provides $350,000 to Adiutrix Therapeutics LLC to develop a novel anti-fibrotic compound platform to identify and develop first-in-class therapeutics targeting collagen prolyl-4 hydroxylase (C-P4H) activity. The goal is to treat tissue remodeling and fibrosis in underserved diseases such as idiopathic pulmonary fibrosis (IPF), scleroderma skin fibrosis, kidney fibrosis, and intestinal fibrosis...

This Project Grant award of $113,090 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research at the University of Pittsburgh to investigate the role of the TGF-β3 protein and its transcriptional regulators in driving myofibroblast differentiation and fibrosis in systemic sclerosis. The key objectives are to: 1) identify the regulatory elements controlling...

This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $100,000.00 to the University of Pittsburgh to study the role of cytokines and inflammatory pathways in systemic sclerosis-associated interstitial lung disease (SSc-ILD). The research aims to refine explant culture methodologies and examine the effects of key cytokines, such as TGF-β, PDGF, IL-6, and IL-13, on lung cell gene expression in healthy control and...

This $110,959 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the mechanisms driving the transition of lipofibroblasts to myofibroblasts in systemic sclerosis, a rare autoimmune fibrosing disease with high mortality. The research aims to define the role of the genes PER3 and CD36 in regulating the lipofibroblast to myofibroblast transition, which is a key driver...

This federal Project Grant award of $805,845 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development and testing of novel lung-targeted therapeutic delivery systems. The goal is to create "precision drug delivery systems" that can actively transport anti-fibrotic agents directly into lung tissue to treat conditions like idiopathic pulmonary fibrosis. Key products/services include engineering...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $464,121 to The Medical University of South Carolina to develop peptides derived from collagen XVIII for the treatment of pulmonary fibrosis. The project aims to simultaneously test the identified peptides in preclinical models of fibrosis, identify a lead candidate, characterize its efficacy, conduct dose escalation...

This federal Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) provides $427,392.00 to The Leland Stanford Junior University to develop a small molecule called SHC301 that inhibits Src Homology and Collagen (SHC) signaling, a non-canonical TGF-β pathway, for the treatment of transplant-related pulmonary fibrosis. The award supports preclinical studies to assess the efficacy of SHC301 in human precision cut lung slices and a mouse orthotopic...